You are here

  • Home
  • Online First
  • Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment

Article Text

Article menu
PDF
Correspondence
Tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment
  1. Young Ho Lee
  1. Division of Rheumatology, Korea University Medical Center, Seoul 02841, South Korea
  1. Correspondence to Professor Young Ho Lee, Division of Rheumatology, Korea University Medical Center, Seoul 02841, South Korea; lyhcgh{at}korea.ac.kr

http://dx.doi.org/10.1136/annrheumdis-2018-214635

Statistics from Altmetric.com

    I was pleased to read the article by Kaneko and colleagues1 on the efficacy and safety of tocilizumab in patients with adult-onset Still’s disease, because the current information on its biologic efficacy has been mainly obtained from small retrospective case series and not from prospective randomised trials. The authors have presented a randomised controlled trial in which they suggest that tocilizumab is effective in adult-onset Still’s disease refractory to glucocorticoid …

    View Full Text

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

    Linked Articles